Development and evaluation of a composite dosage form containing desmopressin acetate for buccal administration
Desmopressin acetate (DDAVP) is an oligopeptide indicated for the treatment of primary nocturnal enuresis, for example. The poor oral bioavailability of DDAVP accelerated a shift to alternative routes of administration like nasal and oromucosal, whereby nasal administration results in high fluctuati...
Saved in:
Main Authors: | Dina Kottke (Author), Bjoern B. Burckhardt (Author), Tanja C. Knaab (Author), Jörg Breitkreutz (Author), Björn Fischer (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2021-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Desmopressin Acetate and Nocturnal Enuresis
by: J Gordon Millichap
Published: (1993) -
A novel dosage form for buccal administration of bupropion
by: Nilsa Maria Galvão Almeida, et al.
Published: (2015) -
Embedding a Sensitive Liquid-Core Waveguide UV Detector into an HPLC-UV System for Simultaneous Quantification of Differently Dosed Active Ingredients during Drug Release
by: Rebecca Chamberlain, et al.
Published: (2022) -
Implementation of a New Electronic Liquid Dispensing System for Individualized Compounding of Hard Capsules
by: Bakul Sarker, et al.
Published: (2022) -
Assay of Desmopressin Acetate in Nasal Spray: Development of Validated Pre Column HPLC-Fluorescence Method
by: Neeraj Upmanyu, et al.
Published: (2017)